Skip to main content
SpringerLink
Log in

The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma

  • Chapter
Advances in Lymphoma Research

Part of the book series: Cancer Treatment and Research ((CTAR,volume 85))

Abstract

Multidrug resistance (MDR) is the term used to describe the phenomenon whereby cancers become resistant to multiple drugs that have little chemical or mechanistic similarity [1,2]. The MDR phenomenon is commonly observed in patients with non-Hodgkin’s lymphoma (NHL). For example, NHL initially responds to a wide variety of chemotherapeutic agents, but most patients eventually develop recurrent disease [3,4]. Recurrent NHL gradually becomes resistant to multiple chemotherapeutic agents, and most patients eventually die of drug-resistant disease [5,6]. MDR is associated with a cell membrane protein called p-glycoprotein (P-gly) [1,2,7]. P-gly is thought to function as an efflux pump removing cytotoxic and xenobiotic agents from cells [8]. P-gly is found in both normal and malignant tissue and may be associated with clinical resistance to chemotherapy in patients with lymphoma [9-11]. Thus, investigations into this molecular mechanism of drug resistance have immediate implications for the clinician treating patients with lymphoma. This chapter focuses on issues that are relevant to the understanding of clinical outcome of patients with lymphoma as it relates to MDR.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gerlach JH, Kartner N, Bell DR, Ling V (1986). Multidrug resistance. Cancer Surv 5:25–46.

    PubMed  CAS  Google Scholar 

  2. Pastan I, Gottesman M (1988). Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393.

    Google Scholar 

  3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993). Phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High Priority study. N Engl J Med 328:1002–1006.

    Article  PubMed  CAS  Google Scholar 

  4. Dana BW, Dahlberg S, Nathwani B, Chase EM, Coltman CA, Miller TP, Fisher RI (1993). Longterm followup of patients with low grade malignant lymphomas treated with doxorubicin based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644–651.

    PubMed  CAS  Google Scholar 

  5. Cabanillas F, Hagemeister FB, McLaughlin P, et al. (1987). MIME combination chemotherapy for refractory or recurrent lymphomas. J Clin Oncol 5:407–412.

    PubMed  CAS  Google Scholar 

  6. Velasquez WS, Cabanillas F, Salvador P, et al. (1988). Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117–122.

    PubMed  CAS  Google Scholar 

  7. Kartner N, Evernden-Porelle O, Bradley G, et al. (1985). Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823.

    Article  PubMed  CAS  Google Scholar 

  8. Juliano RL, Ling V (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biophys Acta 455:152–162.

    Article  CAS  Google Scholar 

  9. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987). Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci 84:265–269.

    Article  PubMed  CAS  Google Scholar 

  10. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar AD, Pirken R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989). Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124.

    Article  PubMed  CAS  Google Scholar 

  11. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9(l):17–24.

    PubMed  CAS  Google Scholar 

  12. Kartner N, Ling V (1989). Multidrug resistance in cancer. Sci Am 44-51.

    Google Scholar 

  13. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987). Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84:7738.

    Article  Google Scholar 

  14. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989). Immunohistochemical localization in normal tissue of different epitopes in a multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histo Chem 37:159.

    Article  CAS  Google Scholar 

  15. Cordon-Cardo C, O’Brien P, Boccia J, Casals D, Bertino JR, Melamed MR (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histo Chem 38:1277.

    Article  CAS  Google Scholar 

  16. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989). Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci 86:695.

    Article  PubMed  CAS  Google Scholar 

  17. Coon JS, Want Y, Bines SD, Markham PH, Chong ASF, Gebel HM (1991). Multidrug resistance activity in human lymphocytes. Hum Immunol 32:134.

    Article  PubMed  CAS  Google Scholar 

  18. Chaudhary PM, Mechetner EB, Roninson IB (1992). Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735–2739.

    PubMed  CAS  Google Scholar 

  19. Chaudhary PM, Roninson IB (1991). Expression and activity of P-glycoprotein in human normal and tumor tissues. Cell 66:85.

    Article  PubMed  CAS  Google Scholar 

  20. Damiani D, Michieli M, Michelutti A, Geromin A, Raspadori D, Fanin R, Savignano C, Giacca M, Pileri S, Mallardi F, Baccarani M (1993). Expression of multidrug resistance gene (MDR-1) in human normal leukocytes. Haematologica 78:12–17.

    PubMed  CAS  Google Scholar 

  21. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992). Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729–2734.

    PubMed  CAS  Google Scholar 

  22. Gupta S, Kim Ch, Tsuruo T, Gollapudi S (1992). Preferential expression and activity of multidrug resistance gene-1 product (P-glycoprotein), a functionally active efflux pump in human CD8+T-cells — a role in cytotoxic effector function. J Clin Immunol 12:451.

    Article  PubMed  CAS  Google Scholar 

  23. Marie JP, Brophy NA, Ahara Y, Mohammed NA, Cornbleet J, Skic BI (1994). Expression of multidrug resistance gene MDR 1 RNA in a subset of normal bone marrow cells. Br J Hematol 81:145.

    Article  Google Scholar 

  24. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O’Brien EE, Poplack DG, Cossman J, Myers CE, Cowan KH (1989). Expression of anionic glutathione-s-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49:1422–1428.

    PubMed  CAS  Google Scholar 

  25. Neyfakh A, Sepinskaya AS, Chervonsky AV, Apasov SG, Kazarov AR (1989). Multidrug resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp Cell Res 185:496.

    Article  PubMed  CAS  Google Scholar 

  26. Pileri S, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli M, Damiani D, Zucchin L, Grobbi M, Tsuruo T, Baccarcini M (1991). Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131–140.

    Article  PubMed  CAS  Google Scholar 

  27. Klimecki WT, Futscher BW, Grogan TM, Dalton WS (1994). P-Glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451–2458.

    PubMed  CAS  Google Scholar 

  28. Grogan TM, Dalton WS, Rybski JA, Spier CM, Meltzer PS, Richter LC, Gleason M, Pindur J, Cline A, Scheper RJ, Tsuro T, Salmon SE (1990). Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies Lab Invest 63(6):815–824.

    PubMed  CAS  Google Scholar 

  29. Dalton WS, Miller TP (1991). Multidrug resistance. In DeVita VT Jr, Hellman S, Rosenberg S (eds), Cancer: Principles and Practice of Oncology, PPO Updates. Philadephia: J.B. Lippincott, pp. 1–13.

    Google Scholar 

  30. Kern WF, Spier CM, Hanneman E, et al. (1992). Neural cell adhesion molecule positive peripheral T cell lymphomas: a rare variant with a propensity for unusual sites of involvement. Blood 79:2432–2437.

    PubMed  CAS  Google Scholar 

  31. Long KF, Chan JK, Ng CS, et al. (1992). CD56-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous mucosal involvement, cytoplasmic azurophilic granules and angiocentricity. Hum Pathol 23:798–804.

    Article  Google Scholar 

  32. Grogan TM, Miller TP (1993). Immunobiologic correlates of prognosis in lymphoma. Semin Oncol 20:58–74.

    PubMed  CAS  Google Scholar 

  33. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH (1993). Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr Virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11:109–115.

    PubMed  CAS  Google Scholar 

  34. Dan S, Esumi M, Sawada U, Hayashi N, Uchida T, Yamazaki T, Ashiya M, Satoh Y, Ohshim T, Horie T, Tsuruo T, Shikata T (1991). Expression of a multi-drug resistance gene in human malignant lymphoma and related disorders. Leuk Res 15:1139–1143.

    Article  PubMed  CAS  Google Scholar 

  35. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, Bloomfeld CD (1992). Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768–3775.

    PubMed  CAS  Google Scholar 

  36. Schlaifer D, Brousset P, Attal M, Voigt JJ, Laurent G, Delsol G (1990). Immunohistochemical detection of multidrug resistance associated P-glycoprotein in stromal cells of malignant lymphomas. Nouv Rev Fr Hematol 32:365–367.

    PubMed  CAS  Google Scholar 

  37. Sugawara I, Karaoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988). Tissue distribution of P-glycoprotein encoded by a multi-drug resistant gene as revealed by a monclonal antibody, MRK 16. Cancer Res 48:1926–1929.

    PubMed  CAS  Google Scholar 

  38. Grogan T, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS (1993). P-glycoprotein-expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490–495.

    PubMed  CAS  Google Scholar 

  39. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP (1991). Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemo-sensitizer. Blood 78:44–50.

    PubMed  CAS  Google Scholar 

  40. Dalton WS, Taylor CW, Mosley K, Dorr RT, Salmon SE (1993). Combination chemotherapy with cyclo?hosphamide(C), vincristine(V), adriamycin(A), dexamethasone(D) (CVAD) plus quinine and verapamil in patients with advanced breast cancer. Proc Am Soc Clin Oncol 12:63 (abstract).

    Google Scholar 

  41. List AF, Spier CM, Greer JP, Wolff S, Hutter J, Dorr RT, Salmon SE, Futscher BW, Baier M, Dalton WS (1993). Phase I/II trial of cyclosporine-A as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11:1652–1660.

    PubMed  CAS  Google Scholar 

  42. Tsuruo T, Iida H, Tsukagoshi S, et al. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972.

    PubMed  CAS  Google Scholar 

  43. Tsuruo T, Iida H, Nojiri M, et al. (1983). Circumvention of vincristine and adriamycin resistance in vitro by calcium efflux blockers. Cancer Res 2905-2910.

    Google Scholar 

  44. Salmon SE, Grogan TM, Miller TP, Scheper RJ, Dalton WS (1989). Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696–701.

    Article  PubMed  CAS  Google Scholar 

  45. Pennock GD, Dalton WS, Roeski WR, et al. (1991). Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105.

    Article  PubMed  CAS  Google Scholar 

  46. Dalton WS, Grogan TM, Meltzer PS, et al. (1989). Drug resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415–424.

    PubMed  CAS  Google Scholar 

  47. Keilhauer C, Emling F, Raschack M, et al. (1989). The use of R-verapamil (R-VPM) is superior to racemic VPM in breaking multidrug resistance of malignant cells. Proc Am Assoc Cancer Res 30:503.

    Google Scholar 

  48. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA (1993). EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol 11:1573–1582.

    PubMed  CAS  Google Scholar 

  49. Sparano JA, Wiernik PH, Leaf A, Dutcher JP (1993). Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin’s lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071–1079.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Thomas P. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen M. Chase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William S. Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas M. Grogan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, USA

    Fernando Cabanillas M.D.  & M. Alma Rodriguez M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Miller, T.P., Chase, E.M., Dalton, W.S., Grogan, T.M. (1997). The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma. In: Cabanillas, F., Rodriguez, M.A. (eds) Advances in Lymphoma Research. Cancer Treatment and Research, vol 85. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4129-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4129-5_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6851-9

  • Online ISBN: 978-1-4615-4129-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation